{平台标识} We deliver structured market intelligence based on earnings analysis and institutional trading patterns. Viridian Therapeutics (NASDAQ: VRDN) has announced the pricing of upsized concurrent public offerings totaling $350 million in aggregate gross proceeds. The financing includes $225 million in convertible senior notes and an equity component, with net proceeds estimated at $334.7 million.
Viridian Therapeutics Prices Upsized $350M Concurrent Public Offerings - EPS Miss Report
News Analysis
© 2026 Market Analysis. All data is for informational purposes only.